Literature DB >> 21185252

A human iPSC model of Hutchinson Gilford Progeria reveals vascular smooth muscle and mesenchymal stem cell defects.

Jinqiu Zhang1, Qizhou Lian, Guili Zhu, Fan Zhou, Lin Sui, Cindy Tan, Rafidah Abdul Mutalif, Raju Navasankari, Yuelin Zhang, Hung-Fat Tse, Colin L Stewart, Alan Colman.   

Abstract

The segmental premature aging disease Hutchinson-Gilford Progeria syndrome (HGPS) is caused by a truncated and farnesylated form of Lamin A called progerin. HGPS affects mesenchymal lineages, including the skeletal system, dermis, and vascular smooth muscle (VSMC). To understand the underlying molecular pathology of HGPS, we derived induced pluripotent stem cells (iPSCs) from HGPS dermal fibroblasts. The iPSCs were differentiated into neural progenitors, endothelial cells, fibroblasts, VSMCs, and mesenchymal stem cells (MSCs). Progerin levels were highest in MSCs, VSMCs, and fibroblasts, in that order, with these lineages displaying increased DNA damage, nuclear abnormalities, and HGPS-VSMC accumulating numerous calponin-staining inclusion bodies. Both HGPS-MSC and -VSMC viability was compromised by stress and hypoxia in vitro and in vivo (MSC). Because MSCs reside in low oxygen niches in vivo, we propose that, in HGPS, this causes additional depletion of the MSC pool responsible for replacing differentiated cells lost to progerin toxicity. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21185252     DOI: 10.1016/j.stem.2010.12.002

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN: 1875-9777            Impact factor:   24.633


  220 in total

1.  Evidence for premature aging due to oxidative stress in iPSCs from Cockayne syndrome.

Authors:  Luciana Nogueira de Sousa Andrade; Jason L Nathanson; Gene W Yeo; Carlos Frederico Martins Menck; Alysson Renato Muotri
Journal:  Hum Mol Genet       Date:  2012-06-01       Impact factor: 6.150

2.  Dedifferentiation rescues senescence of progeria cells but only while pluripotent.

Authors:  Laura J Niedernhofer; Joseph C Glorioso; Paul D Robbins
Journal:  Stem Cell Res Ther       Date:  2011-06-01       Impact factor: 6.832

Review 3.  Diseases in a dish: modeling human genetic disorders using induced pluripotent cells.

Authors:  Gustavo Tiscornia; Erica Lorenzo Vivas; Juan Carlos Izpisúa Belmonte
Journal:  Nat Med       Date:  2011-12       Impact factor: 53.440

Review 4.  Induced pluripotent stem cells--opportunities for disease modelling and drug discovery.

Authors:  Marica Grskovic; Ashkan Javaherian; Berta Strulovici; George Q Daley
Journal:  Nat Rev Drug Discov       Date:  2011-11-11       Impact factor: 84.694

Review 5.  Phenotyping patient-derived cells for translational studies in cardiovascular disease.

Authors:  Stanley Y Shaw; Ari D Brettman
Journal:  Circulation       Date:  2011-11-29       Impact factor: 29.690

6.  Evolution of iPSC disease models.

Authors:  Weiqi Zhang; Zhichao Ding; Guang-Hui Liu
Journal:  Protein Cell       Date:  2012-01       Impact factor: 14.870

Review 7.  Delineating nuclear reprogramming.

Authors:  Jolene Ooi; Pentao Liu
Journal:  Protein Cell       Date:  2012-03-31       Impact factor: 14.870

Review 8.  Cell replacement therapy is the remedial solution for treating Parkinson's disease.

Authors:  Venkatesan Dhivya; Vellingiri Balachandar
Journal:  Stem Cell Investig       Date:  2017-06-30

9.  Modeling of Friedreich ataxia-related iron overloading cardiomyopathy using patient-specific-induced pluripotent stem cells.

Authors:  Yee-Ki Lee; Philip Wing-Lok Ho; Revital Schick; Yee-Man Lau; Wing-Hon Lai; Ting Zhou; Yanhua Li; Kwong-Man Ng; Shu-Leung Ho; Miguel Angel Esteban; Ofer Binah; Hung-Fat Tse; Chung-Wah Siu
Journal:  Pflugers Arch       Date:  2013-12-11       Impact factor: 3.657

Review 10.  Induced pluripotent stem cells: the new patient?

Authors:  Milena Bellin; Maria C Marchetto; Fred H Gage; Christine L Mummery
Journal:  Nat Rev Mol Cell Biol       Date:  2012-10-04       Impact factor: 94.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.